|
Registration benefits include:
|
|
Access to CME/CE programs and certification
|
|
|
Free subscription to Biologic Bulletin newsletter
|
|
|
Reminders of new CME/CE activities
|
 REGISTER NOW
|
|
|
|
|
|
 |
| CME/CE Programs : CE Programs |
Please select from the following activities:
Featured CE Activity
|
|
CME-Certified Biologic Bulletin Edited byJeffrey J. Crowley, MD and Neil J. Korman, MD, PhD
This Biologic Bulletin examines how clinicians can utilize biologics to improve outcomes for their patients with psoriasis. The newsletter highlights some common ways in which patient characteristics can be considered in tailoring treatment decisions. It also examines new data on the long-term safety and efficacy of biologics. This Biologic Bulletin uses a case-based approach to illustrate the clinical decisions involved in developing a treatment strategy for patients with moderate to severe psoriasis.
|
|
Additional CE Activity
|
|
This interactive CME/CNE-certified activity features an update on the pathophysioloy of psoriasis and evolving clinical data on novel agents in clinical development.
Our evolving understanding of the role of new pathways and newly discovered cell populations involved in the pathophysiology of psoriasis offers the potential for novel drug targets and therapeutic agents. A more thorough appreciation of the pathophysiology of psoriasis and the role of certain cell populations and cytokines will help clinicians better understand both the mechanisms of disease and the mechanisms of therapeutic intervention with biologic agents. As novel agents advance in clinical development, clinicians need updates on their mechanisms of action, safety and efficacy profiles, and where they fit into clinical practice.
|
| VIEW ACTIVITY
|
|
|
|
| Co-Chairs: |
Faculty: |
| Scott A. Fretzin, MD |
David J. Cohen, MD |
| Jeffrey M. Weinberg, MD |
Jeffrey J. Crowley, MD |
This interactive CME/CNE-certified activity features an update on current treatment options for this difficult-to-treat condition together with case studies presented by national opinion leaders.
Hand and foot psoriasis is particularly challenging. Many of the older therapies yield less than optimal responses. Emerging reports indicate an important role for biologic agents, and significant improvement has been observed in patients affected with this clinically challenging form of psoriasis. This interactive activity provides an update to health care professionals who treat psoriasis on developing clinical experience in the treatment of hand and foot psoriasis and will also demonstrate the thought processes of experts as they vary therapy to achieve optimal response.
|
| VIEW ACTIVITY
|
|
|
|
|
|
